These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Chen S; Sanjana NE; Zheng K; Shalem O; Lee K; Shi X; Scott DA; Song J; Pan JQ; Weissleder R; Lee H; Zhang F; Sharp PA Cell; 2015 Mar; 160(6):1246-60. PubMed ID: 25748654 [TBL] [Abstract][Full Text] [Related]
49. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Barrangou R; Birmingham A; Wiemann S; Beijersbergen RL; Hornung V; Smith Av Nucleic Acids Res; 2015 Apr; 43(7):3407-19. PubMed ID: 25800748 [TBL] [Abstract][Full Text] [Related]
50. CRISPR-Cas9 for medical genetic screens: applications and future perspectives. Xue HY; Ji LJ; Gao AM; Liu P; He JD; Lu XJ J Med Genet; 2016 Feb; 53(2):91-7. PubMed ID: 26673779 [TBL] [Abstract][Full Text] [Related]
51. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Xie K; Minkenberg B; Yang Y Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3570-5. PubMed ID: 25733849 [TBL] [Abstract][Full Text] [Related]
52. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Maruyama T; Dougan SK; Truttmann MC; Bilate AM; Ingram JR; Ploegh HL Nat Biotechnol; 2015 May; 33(5):538-42. PubMed ID: 25798939 [TBL] [Abstract][Full Text] [Related]
53. Application of CRISPR/Cas9 genome editing to the study and treatment of disease. Pellagatti A; Dolatshad H; Valletta S; Boultwood J Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103 [TBL] [Abstract][Full Text] [Related]
54. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Chu VT; Weber T; Wefers B; Wurst W; Sander S; Rajewsky K; Kühn R Nat Biotechnol; 2015 May; 33(5):543-8. PubMed ID: 25803306 [TBL] [Abstract][Full Text] [Related]
55. Expanding the Biologist's Toolkit with CRISPR-Cas9. Sternberg SH; Doudna JA Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842 [TBL] [Abstract][Full Text] [Related]
56. A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. Parnas O; Jovanovic M; Eisenhaure TM; Herbst RH; Dixit A; Ye CJ; Przybylski D; Platt RJ; Tirosh I; Sanjana NE; Shalem O; Satija R; Raychowdhury R; Mertins P; Carr SA; Zhang F; Hacohen N; Regev A Cell; 2015 Jul; 162(3):675-86. PubMed ID: 26189680 [TBL] [Abstract][Full Text] [Related]
57. CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. Prykhozhij SV; Rajan V; Gaston D; Berman JN PLoS One; 2015; 10(3):e0119372. PubMed ID: 25742428 [TBL] [Abstract][Full Text] [Related]
58. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Kennedy EM; Cullen BR Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096 [TBL] [Abstract][Full Text] [Related]
59. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? Taylor J; Woodcock S J Biomol Screen; 2015 Sep; 20(8):1040-51. PubMed ID: 26048892 [TBL] [Abstract][Full Text] [Related]
60. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Hilton IB; D'Ippolito AM; Vockley CM; Thakore PI; Crawford GE; Reddy TE; Gersbach CA Nat Biotechnol; 2015 May; 33(5):510-7. PubMed ID: 25849900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]